ADR Biomedical HoldingsADR Biomedical Holdings Inc.3750東証スタンダード情報・通信業FY ending Mar 2026, consolidated, J-GAAP
It lost about ¥1777 for every ¥100 of sales at the operating level. Revenue changed -58.3% from the prior year.
Net margin × asset turnover = ROA; ROA × financial leverage = ROE
| Period | Net margin | Asset turnover | ROA | Financial leverage | ROE |
|---|---|---|---|---|---|
| 2022 | — | —× | -0.5% | —× | — |
| 2023 | — | —× | -7.0% | —× | — |
| 2024 | 8.9% | 0.16× | 1.4% | 3.97× | 5.5% |
| 2025 | — | —× | -45.8% | —× | — |
| 2026 | — | —× | -20.3% | —× | — |
Financial leverage can raise ROE; a higher value alone does not describe a company's overall condition.
Annual trends in tangible-asset ratios and goodwill balance.
Ratios are derived from reported values. Goodwill is shown only when separately reported; it is not inferred from combined intangible assets. Definition
Track R&D investment and how long operating capital remains tied up before sales turn into cash.
R&D is shown only for years with machine-readable disclosure. Days are estimates using year-end receivables, inventory and payables divided by annual revenue or cost of sales; financial companies are excluded.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 1,336 | 2,145 | 1,560 | 122 | 51 |
| Cost of revenue | 476 | 876 | 268 | 128 | 40 |
| Gross profit | 859 | 1,269 | 1,293 | -6 | 11 |
| SG&A | 1,322 | 2,063 | 2,065 | 801 | 917 |
| Operating income | -462 | -794 | -773 | -807 | -906 |
| Pretax income | -65 | -1,166 | -1,011 | -2,153 | -398 |
| Income tax | 12 | -106 | -1,150 | -13 | -1 |
| Net income attributable to owners | -78 | -1,060 | 138 | -2,140 | -397 |
| Operating margin | -34.6% | -37.0% | -49.5% | -660.3% | -1777.2% |
Year-end figures from filings. Unreported items are omitted. Interest-bearing debt excludes lease liabilities.
Each bar totals 100% of assets; other is the residual.
| Item | FY ending Mar 2022 | FY ending Mar 2023 | FY ending Mar 2024 | FY ending Mar 2025 | FY ending Mar 2026 |
|---|---|---|---|---|---|
| Cash and equivalents | ¥701.6M | ¥673M | ¥1.04B | ¥256M | ¥125.9M |
| Total assets | ¥16B | ¥14.1B | ¥5.82B | ¥3.54B | ¥368.1M |
| Net assets | ¥3.72B | ¥2.66B | ¥2.8B | ¥630.5M | ¥22M |
| Share capital | ¥100M | ¥100M | ¥100M | ¥100M | ¥100M |
| Property, plant and equipment | ¥12B | ¥11.7B | ¥4.22B | ¥2.96B | ¥0 |
| Intangible assets excluding goodwill | ¥742.5M | ¥688.8M | ¥21.3M | ¥2M | — |
| Goodwill | ¥693.1M | ¥647.1M | — | — | — |
| Investment securities | — | — | — | ¥250K | ¥10.3M |
| Current assets | ¥3.03B | ¥1.39B | ¥1.43B | ¥517.2M | ¥350.5M |
| Current liabilities | ¥995.5M | ¥1.17B | ¥536.2M | ¥491.8M | ¥226.7M |
| Short-term borrowings | ¥164.3M | ¥500M | ¥70M | ¥300M | — |
| Long-term borrowings | ¥8.55B | ¥7.61B | ¥2.35B | ¥2.29B | — |
| Total liabilities | ¥12.3B | ¥11.4B | ¥3.02B | ¥2.91B | ¥346M |
| Non-controlling interests | ¥3.8M | ¥4M | ¥4.8M | — | — |
| Equity attributable to owners of parent | ¥3.5B | ¥2.44B | ¥2.58B | ¥419M | ¥22M |
| Retained earnings | ¥462.8M | -¥596.9M | -¥458.8M | -¥2.62B | -¥3.02B |
| Treasury stock | -¥982K | -¥1.2M | -¥1.5M | -¥1.5M | -¥1.6M |
EDINET (FSA Japan)
有価証券報告書－第22期(2025/04/01－2026/03/31)
EDINET (FSA Japan)
訂正有価証券報告書－第21期(2024/04/01－2025/03/31)
EDINET (FSA Japan)
有価証券報告書－第20期(2023/04/01－2024/03/31)
EDINET (FSA Japan)
訂正有価証券報告書－第19期(2022/04/01－2023/03/31)
EDINET (FSA Japan)
有価証券報告書－第18期(令和3年4月1日－令和4年3月31日)
EDINET (FSA Japan)
有価証券報告書－第17期(令和2年4月1日－令和3年3月31日)
Extracted from XBRL: 42
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.